| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Outline of Final Research Achievements |
Bisphosphonate (BP) and anti-RANKL antibody are widely used as anti-resorptive agents for bone metastasis and osteoporosis. Although these agents have different effect mechanism, thay can sometimes result in osteonecrosis of the jaw (ONJ). We examined that these agents were different influence for the bone formation by osteocyte and osteoblast in long bones. This was evident in ovariectomized C57BL/6J mice, which were treated with zoledronic acid (ZOL) or anti-RANKL antibody. Bone mass in long bone of both mice groups treated with ZOL and anti-RANKL antibody under lack of estrogen had significantly increased compared to control mice. Additionally, the changes in the expression of bone formation-related genes (Sost, Dmp1, and Osteocalcin) in long bones of mice treated with either ZOL or anti-RANKL antibody was different. Thus, these results suggested that the regulatory mechanisms of bone formation in osteocytes and osteoblasts differs between BP and anti-RANKL antibody.
|
